The Speers laboratory research includes nomination and validation of expression-based signatures to predict patients that need treatment intensification and signatures to identify patient who will not need further adjuvant therapy for breast cancer. Moreover, our translational work has credentialed a number of novel targets for the treatment of estrogen and progesterone receptor-negative, HER2-negative “triple-negative” breast cancer, a particularly aggressive and difficult to treat form of breast cancer. As PI or co-Investigator on several university-, industry-, private foundation- and NIH-funded grants, we remain active in the radiation and breast cancer research arena by looking for more effective, targeted therapies for women with breast cancer. These targeted therapies include PARP-inhibitors, BET bromodomain inhibitors, and androgen receptor antagonists as agents for radiosensitization. We have also utilized kinome screens to identify novel targets for the treatment of aggressive breast cancers, including triple-negative breast cancer. Finally, we are also interested in the mechanisms of treatment resistance that include modulation of breast tumor initiating cells and understanding novel layers of cancer biology, including the role of long non-coding RNA in triple-negative breast cancer.
Clinical and scientific interests include using genomic and proteomic approaches to identify women who are at high risk for breast cancer recurrence and who may benefit from treatment intensification. Interests also include molecularly based signatures to identifying women who are cured after breast conserving surgery and who may not require adjuvant radiation.
Radiation Therapy for Breast Cancer
Radiation therapy for breast cancer- Interest includes identifying novel molecular targets for chemo‐ and radio-sensitization in women with triple‐negative or basal‐like breast cancer, including those molecules critical for maintaining breast cancer stem cells.
Radiation Therapy for Prostate Cancer
Radiation therapy for prostate cancer- Interest includes the identification of molecular targets relevant for the systemic progression and radiation sensitization of prostate cancer.
- Michmerhuizen, Anna R.*, Andrea M. Pesch*, Leah Moubadder, Benjamin C. Chandler, Kari Wilder-Romans, Meleah Cameron, Eric Olsen et al. "PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation." Molecular cancer therapeutics (2019): molcanther-0520.
- Speers, Corey, Shuang G. Zhao, Ben Chandler, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati et al. "Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer." NPJ Breast Cancer 3, no. 1 (2017): 29.
- Speers, Corey, Shuang G. Zhao, Vishal Kothari, Alyssa Santola, Meilan Liu, Kari Wilder-Romans, Joseph Evans et al. "Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer." Clinical Cancer Research 22, no. 23 (2016): 5864-5875.
Please contact Corey Speers, MD, PhD if you are interested in working with the Speers Lab.